Drug intelligence / Profile preview

SapK573

Development stage: Unknown
Lead developer: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

SapK573 is an investigational therapeutic cancer vaccine developed by the Cancer Hospital of the Chinese Academy of Medical Sciences. It is designed to target KRAS-mutated advanced solid tumors by stimulating the immune system to recognize and eliminate cancer cells expressing mutant KRAS proteins. The vaccine is currently undergoing a Phase 1 clinical trial (ChiCTR2500113691) in China to evaluate its safety, tolerability, immunogenicity, and preliminary antitumor activity in patients who have failed standard treatments.

Other names: SapK573 tumor vaccineSapK-573 tumor vaccineSapK 573 tumor vaccine

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on SapK573.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SapK573.

Explore the full profile